{"Whether": [0], "pembrolizumab": [1, 16, 72, 80, 279, 291], "given": [2, 17], "both": [3, 280], "before": [4, 281], "surgery": [5, 10, 77, 284], "(neoadjuvant": [6], "therapy)": [7], "and": [8, 67, 224, 256, 282, 305, 308], "after": [9, 157, 162, 283], "(adjuvant": [11], "therapy),": [12], "as": [13, 18, 122], "compared": [14], "with": [15, 28, 45, 239, 263], "adjuvant": [19, 71, 152, 290], "therapy": [20, 153, 249], "alone,": [21], "would": [22], "increase": [23], "event-free": [24, 113, 187, 206, 270], "survival": [25, 114, 188, 207, 271], "among": [26, 275, 286], "patients": [27, 44, 238, 262], "resectable": [29, 264], "stage": [30, 49, 265], "III": [31, 266], "or": [32, 75, 97, 101, 125, 142, 164, 246, 267], "IV": [33, 268], "melanoma": [34, 53, 161], "is": [35], "unknown.In": [36], "a": [37, 88, 173, 203], "phase": [38], "2": [39, 209], "trial,": [40], "we": [41], "randomly": [42], "assigned": [43], "clinically": [46], "detectable,": [47], "measurable": [48], "IIIB": [50], "to": [51, 57, 60, 76, 133, 218, 229], "IVC": [52], "that": [54, 128, 147], "was": [55, 112, 170, 211, 250, 272], "amenable": [56], "surgical": [58, 140], "resection": [59], "three": [61], "doses": [62, 69], "of": [63, 70, 90, 145, 151, 160, 176, 237, 243], "neoadjuvant": [64], "pembrolizumab,": [65], "surgery,": [66], "15": [68], "(neoadjuvant-adjuvant": [73], "group)": [74], "followed": [78], "by": [79, 198, 300], "(200": [81], "mg": [82], "intravenously": [83], "every": [84], "3": [85, 245], "weeks": [86], "for": [87, 93], "total": [89], "18": [91], "doses)": [92], "approximately": [94], "1": [95], "year": [96], "until": [98], "disease": [99, 123, 138], "recurred": [100], "unacceptable": [102], "toxic": [103, 126, 143, 295], "effects": [104, 127, 144, 296], "developed": [105], "(adjuvant-only": [106], "group).": [107], "The": [108, 235], "primary": [109], "end": [110], "point": [111], "in": [115, 220, 231, 252, 258], "the": [116, 131, 149, 179, 190, 199, 221, 232, 253, 259, 301], "intention-to-treat": [117], "population.": [118], "Events": [119], "were": [120, 297], "defined": [121], "progression": [124], "precluded": [129, 148], "surgery;": [130, 158, 163], "inability": [132], "resect": [134], "all": [135], "gross": [136], "disease;": [137], "progression,": [139], "complications,": [141], "treatment": [146], "initiation": [150], "within": [154], "84": [155], "days": [156], "recurrence": [159], "death": [165], "from": [166], "any": [167], "cause.": [168], "Safety": [169], "also": [171], "evaluated.At": [172], "median": [174], "follow-up": [175], "14.7": [177], "months,": [178], "neoadjuvant-adjuvant": [180, 222, 254], "group": [181, 192, 223, 255], "(154": [182], "patients)": [183, 194], "had": [184], "significantly": [185, 273], "longer": [186, 274], "than": [189, 285], "adjuvant-only": [191, 233, 260], "(159": [193], "(P": [195], "=": [196], "0.004": [197], "log-rank": [200], "test).": [201], "In": [202], "landmark": [204], "analysis,": [205], "at": [208], "years": [210], "72%": [212], "(95%": [213, 226], "confidence": [214], "interval": [215], "[CI],": [216], "64": [217], "80)": [219], "49%": [225], "CI,": [227], "41": [228], "59)": [230], "group.": [234], "percentage": [236], "treatment-related": [240], "adverse": [241], "events": [242], "grades": [244], "higher": [247], "during": [248], "12%": [251], "14%": [257], "group.Among": [261], "melanoma,": [269], "those": [276, 287], "who": [277, 288], "received": [278, 289], "alone.": [292], "No": [293], "new": [294], "identified.": [298], "(Funded": [299], "National": [302], "Cancer": [303], "Institute": [304], "Merck": [306], "Sharp": [307], "Dohme;": [309], "S1801": [310], "ClinicalTrials.gov": [311], "number,": [312], "NCT03698019.).": [313]}